Disease relevance of cyaC

• Purified active and inactive CyaA proteins were prepared from B. pertussis or from recombinant Escherichia coli expressing both cyaA and cyaC genes or the cyaA gene alone. respectively [1].
• Characterization of adenylate cyclase toxin from a mutant of Bordetella pertussis defective in the activator gene, cyaC [2].

High impact information on cyaC

• In that AC toxin from BPDE386 is able to function normally when injected artificially to an intracellular site, we conclude that the disruption of cyaC produces a defect in insertion and transmembrane delivery of the catalytic domain [2].
• AC-Hly possesses both adenylate cyclase toxic and hemolytic activities that depend on a posttranslational modification mediated by the product of the cyaC gene [3].
• The role of the cyaC gene product in the acylation reaction has not been determined [4].
• Activation to the mature cell-invasive toxin involves palmitoylation of lysine 983 and is dependent on co-expression of cyaC [4].
• The cyaB, D and E gene products are necessary for CyaA transport, and the cyaC gene product is required to activate CyaA [5].

Chemical compound and disease context of cyaC

• Bordetella pertussis adenylate cyclase (AC) toxin has the abilities to 1) enter target cells where it catalyzes cyclic AMP production and 2) lyse sheep erythrocytes, and these abilities require post-translational modification by the product of an accessory gene cyaC (Barry, E [2].

Other interactions of cyaC

• Bordetella pertussis produces a cell-invasive adenylate cyclase toxin which is synthesised from the cyaA gene as an inactive protoxin that is post-translationally activated by the product of the cyaC gene [1].

References